These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 9777975

  • 21. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis.
    Kantor J, Margolis DJ.
    Dermatol Surg; 2001 Apr; 27(4):347-51. PubMed ID: 11298704
    [Abstract] [Full Text] [Related]

  • 22. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. Diabetic Ulcer Study Group.
    Steed DL.
    J Vasc Surg; 1995 Jan; 21(1):71-8; discussion 79-81. PubMed ID: 7823364
    [Abstract] [Full Text] [Related]

  • 23. [Approval for recombinant growth factor. Since January 2000, patients with diabetic foot ulcers can be treated with the growth factor becaplermin (Regranex), manufactured with genetic technology].
    Fruhstorfer B.
    Internist (Berl); 2000 Jan; 41(1):A38. PubMed ID: 10712088
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. A review of nonclinical toxicology studies of becaplermin (rhPDGF-BB).
    Knight EV, Oldham JW, Mohler MA, Liu S, Dooley J.
    Am J Surg; 1998 Aug; 176(2A Suppl):55S-60S. PubMed ID: 9777973
    [Abstract] [Full Text] [Related]

  • 26. Benefit-risk assessment of becaplermin in the treatment of diabetic foot ulcers.
    Papanas N, Maltezos E.
    Drug Saf; 2010 Jun 01; 33(6):455-61. PubMed ID: 20486728
    [Abstract] [Full Text] [Related]

  • 27. Treatment of scleroderma skin ulcers using becaplermin gel and hydrocolloid membrane.
    Yoon J, Giacopelli J, Granoff D, Kobayashi W.
    J Am Podiatr Med Assoc; 2002 Jun 01; 92(6):350-4. PubMed ID: 12070235
    [Abstract] [Full Text] [Related]

  • 28. Treatment of stingray injury with topical becaplermin gel.
    Baldinger PJ.
    J Am Podiatr Med Assoc; 1999 Oct 01; 89(10):531-3. PubMed ID: 10546426
    [Abstract] [Full Text] [Related]

  • 29. The future of recombinant growth factors in wound healing.
    Robson MC, Mustoe TA, Hunt TK.
    Am J Surg; 1998 Aug 01; 176(2A Suppl):80S-82S. PubMed ID: 9777977
    [Abstract] [Full Text] [Related]

  • 30. Which is the better option: recombinant human PDGF-BB 0.01% gel or standard wound care, in diabetic neuropathic large plantar ulcers off-loaded by a customized contact cast?
    Bhansali A, Venkatesh S, Dutta P, Dhillon MS, Das S, Agrawal A.
    Diabetes Res Clin Pract; 2009 Jan 01; 83(1):e13-6. PubMed ID: 19081156
    [Abstract] [Full Text] [Related]

  • 31. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers.
    Steed DL.
    Plast Reconstr Surg; 2006 Jun 01; 117(7 Suppl):143S-149S; discussion 150S-151S. PubMed ID: 16799381
    [Abstract] [Full Text] [Related]

  • 32. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers.
    Robson MC, Phillips LG, Thomason A, Robson LE, Pierce GF.
    Lancet; 1992 Jan 04; 339(8784):23-5. PubMed ID: 1345953
    [Abstract] [Full Text] [Related]

  • 33. Effect of platelet-derived growth factor-BB on bone formation in calvarial defects: an experimental study in rabbits.
    Vikjaer D, Blom S, Hjørting-Hansen E, Pinholt EM.
    Eur J Oral Sci; 1997 Feb 04; 105(1):59-66. PubMed ID: 9085030
    [Abstract] [Full Text] [Related]

  • 34. The use of becaplermin (rhPDGF-BB) gel for chronic nonhealing ulcers. A retrospective analysis.
    Mandracchia VJ, Sanders SM, Frerichs JA.
    Clin Podiatr Med Surg; 2001 Jan 04; 18(1):189-209, viii. PubMed ID: 11344978
    [Abstract] [Full Text] [Related]

  • 35. Diabetic foot ulcers treated with becaplermin and TheraGauze, a moisture-controlling smart dressing: a randomized, multicenter, prospective analysis.
    Landsman A, Agnew P, Parish L, Joseph R, Galiano RD.
    J Am Podiatr Med Assoc; 2010 Jan 04; 100(3):155-60. PubMed ID: 20479444
    [Abstract] [Full Text] [Related]

  • 36. A phase II study to evaluate recombinant platelet-derived growth factor-BB in the treatment of stage 3 and 4 pressure ulcers.
    Mustoe TA, Cutler NR, Allman RM, Goode PS, Deuel TF, Prause JA, Bear M, Serdar CM, Pierce GF.
    Arch Surg; 1994 Feb 04; 129(2):213-9. PubMed ID: 8304833
    [Abstract] [Full Text] [Related]

  • 37. Cost-effective management of recalcitrant diabetic foot ulcers.
    Albert S.
    Clin Podiatr Med Surg; 2002 Oct 04; 19(4):483-91. PubMed ID: 12471856
    [Abstract] [Full Text] [Related]

  • 38. The nitric oxide connection: hyperbaric oxygen therapy, becaplermin, and diabetic ulcer management.
    Boykin JV.
    Adv Skin Wound Care; 2000 Oct 04; 13(4 Pt 1):169-74. PubMed ID: 11075012
    [Abstract] [Full Text] [Related]

  • 39. Platelet-rich plasma: support for its use in wound healing.
    Lacci KM, Dardik A.
    Yale J Biol Med; 2010 Mar 04; 83(1):1-9. PubMed ID: 20351977
    [Abstract] [Full Text] [Related]

  • 40. Clinicopathologic reports, case reports, and small case series: 0.01% becaplermin gel for the treatment of a chronic orbital ulcer after exenteration.
    Yassur I, Hirschbein MJ, Karesh JW.
    Arch Ophthalmol; 2001 Dec 04; 119(12):1858-9. PubMed ID: 11735804
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.